Efficacy and Safety of Denosumab vs Zoledronic Acid in OI Adults: A Prospective, Open-Label, Randomized Study

Xiaoyun Lin,Jing Hu,Bingna Zhou,Xiaojie Wang,Qian Zhang,Yan Jiang,Ou Wang,Weibo Xia,Xiaoping Xing,Mei Li
DOI: https://doi.org/10.1210/clinem/dgae012
2024-01-05
The Journal of Clinical Endocrinology & Metabolism
Abstract:Abstract Context The comparative effectiveness of denosumab and zoledronic acid for adult patients with osteogenesis imperfecta (OI) has not been established. Objective To evaluate the efficacy and safety of denosumab and zoledronic acid in adult patients with OI. Methods This was a prospective, open-label study. Patients were randomized to receive denosumab 60 mg every 6 months or zoledronic acid 5 mg once for 12 months. Pathogenic mutations of OI were identified by next-generation sequencing and confirmed by Sanger sequencing. Percentage changes in the areal bone mineral density (aBMD), trabecular bone score (TBS), and bone turnover biomarkers (BTMs) from baseline to 6 and 12 months of treatment, as well as safety, were evaluated. Results A total of 51 adults with OI (denosumab: 25, zoledronic acid: 26) were included, of whom 49 patients had identified pathogenic mutations. At 12 months, aBMD at the lumbar spine and total hip significantly increased by 4.34% (P = .005) and 1.45% (P = .023) in the denosumab group and by 4.92% (P = .006) and 2.02% (P = .016) in the zoledronic acid group, respectively. TBS showed an increasing trend by 1.39% and 2.70% in denosumab and zoledronic acid groups, respectively. Serum levels of β-isomerized carboxy-telopeptide of type I collagen and alkaline phosphatase markedly decreased after denosumab treatment. Percentage changes in aBMD, TBS, and BTMs during the treatment were similar between the 2 groups. Patients with OI with milder phenotypes showed a significantly higher increase in the TBS after 12 months of denosumab treatment than those with more severe phenotypes (P = .030). During the study period, the denosumab group had fewer adverse events than the zoledronic acid group. Conclusion Denosumab effectively increases aBMD in adults with OI, with similar efficacy to zoledronic acid. Long-term and large-sample studies are needed to confirm the antifracture efficacy and safety of denosumab in adult patients with OI.
endocrinology & metabolism
What problem does this paper attempt to address?
This paper aims to address the comparison of the efficacy and safety between Denosumab and Zoledronic Acid in adult patients with Osteogenesis Imperfecta (OI). Specifically, the main objective of the study is to evaluate the effects of these two drugs in increasing the areal bone mineral density (aBMD) of adult patients with Osteogenesis Imperfecta and compare their safety. ### Research Background Osteogenesis Imperfecta is a genetic bone disease, characterized by fragile bones, susceptibility to fractures, skeletal deformities and growth retardation. Adult patients with Osteogenesis Imperfecta face a high risk of fractures throughout their lives due to low bone density and high bone material density. Currently, the main treatment method for Osteogenesis Imperfecta is to reduce the incidence of fractures. Bisphosphonates (BPs) have been widely used in the treatment of Osteogenesis Imperfecta in children, but their efficacy in adult patients is limited, especially in patients with severe Osteogenesis Imperfecta. Therefore, it is urgent to explore new treatment methods. Denosumab, as a monoclonal antibody targeting RANKL, has been approved for the treatment of post - menopausal osteoporosis and male osteoporosis, showing the effects of inhibiting osteoclast activity, increasing bone density and reducing the risk of fractures. ### Research Design This is a 12 - month prospective, randomized, open - label study. Adult patients with Osteogenesis Imperfecta were randomly assigned to receive a 60 - mg subcutaneous injection of Denosumab every 6 months or a one - time 5 - mg intravenous infusion of Zoledronic Acid. All patients were supplemented with 600 mg of calcium and 0.25 μg of calcitriol daily. ### Main Research Results - **Bone Density Changes**: - In the Denosumab group, at 12 months, the aBMD of the lumbar spine (LS) and total hip (TH) increased significantly by 4.34% (P = 0.005) and 1.45% (P = 0.023), respectively. - In the Zoledronic Acid group, at 12 months, the aBMD of the lumbar spine and total hip increased significantly by 4.92% (P = 0.006) and 2.02% (P = 0.016), respectively. - There was no significant difference in the change of aBMD between the two groups (P > 0.05). - **Trabecular Bone Score (TBS)**: - At 12 months, the TBS in the Denosumab group and the Zoledronic Acid group increased by 1.39% and 2.70%, respectively, but did not reach statistical significance. - There was no significant difference in the change of TBS between the two groups (P > 0.05). - **Bone Turnover Markers (BTMs)**: - After Denosumab treatment, the serum β - CTX level decreased significantly (6 months: 49.71 ± 9.20%, 12 months: 45.64 ± 10.45%). - After Zoledronic Acid treatment, the serum β - CTX level also decreased significantly (6 months: 59.88 ± 24.61%, 12 months: 49.18 ± 35.51%). - There was no significant difference in the change of β - CTX level between the two groups (P > 0.05). - **New Fractures**: - Within 12 months, there were 2 new fractures in the Denosumab group and 1 new fracture in the Zoledronic Acid group, with no significant difference between the two groups. ### Safety - The incidence of adverse events (AEs) in the Denosumab group was significantly lower than that in the Zoledronic Acid group (20.0% vs 53.8%, P = 0.012), mainly because the incidence of acute - phase reactions in the Denosumab group was lower (0.0% vs 34.6%, P = 0.002). - Other AEs included bone pain, injection - site reactions and fatigue, all of which were mild and did not lead to treatment interruption. ### Conclusion Denosumab significantly increased the aBMD of the lumbar spine and total hip in adult patients with Osteogenesis Imperfecta, and its efficacy was equivalent to that of Zoledronic Acid, but the incidence of adverse events in Denosumab was lower. In addition, patients with Osteogenesis Imperfecta with a dominant inheritance pattern may respond better to Denosumab, as shown by a significant increase in TBS at 12 months. Long - term and large - sample studies are still needed to further confirm the anti - fracture efficacy and safety of Denosumab in adult patients with Osteogenesis Imperfecta.